Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Lamprini Veneti et al.
Summary: There was no difference in the risk of hospitalization between Delta variant cases and Alpha variant cases in Norway. Partially vaccinated and fully vaccinated cases had a lower risk of hospitalization compared to unvaccinated cases.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Antonio Vitiello et al.
IRISH JOURNAL OF MEDICAL SCIENCE
(2022)
Letter
Medicine, General & Internal
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Shi-Yan Ren et al.
Summary: This review summarizes the highly mutated regions, infectivity, transmission, vaccine breakthrough, and antibody resistance of the SARS-CoV-2 variant Omicron. Omicron is highly transmissible and may cause milder symptoms. Vaccines are less effective against the Omicron variant.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Review
Cell Biology
Yu-Chyi Hwang et al.
Summary: The COVID-19 pandemic has created a public health crisis, leading to the urgent development of therapeutic treatments and virus detection methods. Monoclonal antibodies (mAbs) have emerged as powerful tools for treating and detecting diseases due to their high specificity and reliability. Researchers are urgently developing antibody-based kits for SARS-CoV-2 detection and antibody drugs for COVID-19 treatment. The spike protein of SARS-CoV-2, which is crucial for viral infection, has been extensively studied and its receptor-binding domain (RBD) has become a major target for therapeutic antibody development. Given the high mutation rate of SARS-CoV-2, especially under the pressure of prophylactic vaccines and neutralizing antibodies, the use of antibody cocktails is expected to be an important strategy for effective COVID-19 treatment. Additionally, antibodies against cytokine storms, which can be triggered by SARS-CoV-2 infection and drive severe disease progression, are also being developed as treatments for COVID-19. In addition to their use as drugs, antibodies are currently being used in SARS-CoV-2 detection tests, including antigen and immunoglobulin tests, which are crucial surveillance tools for preventing the spread of COVID-19.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
News Item
Multidisciplinary Sciences
Ewen Callaway
Article
Medicine, General & Internal
Marina Di Domenico et al.
Summary: The global pandemic of COVID-19 has created an unprecedented public health emergency, highlighting the importance of early identification of infected individuals and disruption of transmission pathways. This study aims to provide a rapid and sensitive method for diagnosing SARS-CoV-2 infection, with the goal of reducing the spread of the virus.
Article
Pharmacology & Pharmacy
Jianyuan Zhao et al.
Summary: Antiviral therapeutics are crucial in combating the COVID-19 pandemic, and a cell-based assay for SARS-CoV-2 RdRp has been developed to evaluate the efficacy of nucleotide analog inhibitors and their resistance to viral exoribonuclease-mediated proofreading. Molnupiravir and Remdesivir showed strong inhibition of SARS-CoV-2 RdRp, with Molnupiravir demonstrating the lowest EC50 value and Remdesivir having the highest resistance to exoribonuclease activity.
ANTIVIRAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Davide Corti et al.
Summary: Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity, and infectious diseases. Lessons learned from the COVID-19 pandemic have paved the way for the development of more monoclonal antibody-based therapeutics.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Review
Virology
Anna Winger et al.
Summary: The high sequence identity of the initial SARS-CoV-2 samples collected in Wuhan in December 2019 did not predict the emergence of novel variants in different regions around the world. The viral spike receptor has two areas of high mutagenic plasticity, with mutations mainly focusing on the N-terminal domain and receptor binding domain. The evolution of spike mutations, including the characteristic D614G mutation, continues to drive the development of new variants.
Article
Environmental Sciences
Marina Di Domenico et al.
Summary: The study evaluated the diagnostic accuracy of a new cyto-salivary antigen test for detecting SARS-CoV-2 antigens, showing a sensitivity of 100% and specificity of 94.2%. In comparison, the lateral flow test had a sensitivity of 55% and specificity of 100%.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Microbiology
Jiri Zahradnik et al.
Summary: In vitro evolution of the SARS-CoV-2 spike protein receptor-binding domain successfully generated a high-affinity variant effective in inhibiting virus infection. Mutations present in more transmissible viruses were preferentially selected, and increased affinity to ACE2 was positively correlated with the incidence of RBD mutations in the population. The study also identified mutations with potential higher infectivity, and the high-affinity RBD variant showed efficacy in inhibiting infection in vitro and reducing clinical disease in a hamster model of SARS-CoV-2 challenge.
NATURE MICROBIOLOGY
(2021)
Letter
Biochemistry & Molecular Biology
Xiantao Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Multidisciplinary Sciences
Daniel Wrapp et al.
News Item
Multidisciplinary Sciences
Kai Kupferschmidt et al.
Article
Genetics & Heredity
Rozhgar A. Khailany et al.
